Hancock Whitney Corp Cuts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hancock Whitney Corp trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.5% during the 1st quarter, HoldingsChannel reports. The firm owned 5,430 shares of the biopharmaceutical company’s stock after selling 439 shares during the quarter. Hancock Whitney Corp’s holdings in Halozyme Therapeutics were worth $221,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in shares of Halozyme Therapeutics by 24.0% during the 1st quarter. Janus Henderson Group PLC now owns 531,125 shares of the biopharmaceutical company’s stock worth $21,604,000 after acquiring an additional 102,911 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its position in Halozyme Therapeutics by 2.0% during the first quarter. Silvercrest Asset Management Group LLC now owns 603,137 shares of the biopharmaceutical company’s stock valued at $24,536,000 after purchasing an additional 11,805 shares during the last quarter. Epoch Investment Partners Inc. grew its stake in shares of Halozyme Therapeutics by 23.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after buying an additional 270,579 shares in the last quarter. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $225,000. Finally, Advisors Asset Management Inc. raised its position in shares of Halozyme Therapeutics by 6.2% during the 1st quarter. Advisors Asset Management Inc. now owns 43,059 shares of the biopharmaceutical company’s stock valued at $1,752,000 after buying an additional 2,505 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 109,755 shares in the company, valued at approximately $5,488,847.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 109,755 shares in the company, valued at approximately $5,488,847.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,000 shares of company stock worth $2,294,050. Company insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of several recent research reports. JMP Securities dropped their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. The Goldman Sachs Group raised their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Benchmark boosted their price objective on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $48.00 to $51.00 in a report on Friday, June 7th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $58.38.

Halozyme Therapeutics Trading Down 1.6 %

Shares of NASDAQ:HALO traded down $0.88 on Friday, hitting $54.17. 409,449 shares of the company’s stock were exchanged, compared to its average volume of 1,243,763. The business’s 50 day simple moving average is $51.08 and its two-hundred day simple moving average is $43.26. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The stock has a market capitalization of $6.89 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $57.08.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.07. The company had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. Analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.